Next Generation CAR & T Cell Therapies is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Stephen Santoro
Principal Scientist at Kite Pharma, a Gilead Company, USA


Stephen Santoro joined Kite/Gilead through the acquisition of Cell Design labs in 2017. While with Cell Design Labs, Stephen focused on the development of switchable CAR T technologies and associated next-generation tools. Currently, Stephen is leading Kite/Gilead’s internal multiple myeloma and acute myeloid leukemia research efforts.

Prior to joining Cell design labs, Stephen completed a postdoc at Genentech where he explored the role of the tumor stroma on checkpoint blockade and immunotherapy. Trained as a CAR T cell biologist at the University of Pennsylvania, Stephen believes that modulation of the tumor microenvironment using synthetic biology holds the key to successful CAR T cell therapy across multiple solid and semi-solid tumors

Stephen Santoro's Network

Agenda Sessions

  • Small molecule CAR T cell control: making the Switch

    , 2:15pm